Evaluation of Dermatologic Adverse Events Associated with Aromatase Inhibitors: Insights from the FAERS Database

This study analyzed data from the FDA Adverse Event Reporting System to evaluate dermatologic adverse events (AEs) associated with aromatase inhibitors (AIs) from 2004 to 2024. Out of over 21 million AE reports, 2,237 involved skin issues, with 61 preferred terms showing positive signals, including nail disorders and abnormal hair growth. The highest associations were with pseudo cellulitis, anhidrosis, and nail toxicity. Anastrozole and exemestane showed strong associations with dermatologic AEs, while letrozole did not. Onset times for these AEs varied, with some occurring as early as 2 days. The study underscores the need for dermatologic monitoring during AI therapy and further research into AI-induced dermatologic AEs.